Global Intravenous Immunoglobulin (IVIg) Market Research Report - Forecast To 2023

Report / Search Code: MRFR/Pharma/2259-HCRR  Publish Date: May, 2019

Price

<table>
<thead>
<tr>
<th></th>
<th>1-user PDF : $ 4450.0</th>
<th>Enterprise PDF : $ 6250.0</th>
</tr>
</thead>
</table>

Description:

Global Intravenous Immunoglobulin (IVIg) Market information, by type (IgA, IgD, IgE, IgG, IgM), by Application (Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia, Multifocal Motor Neuropathy, Immunodeficiency diseases, Primary Humoral Immunodeficiency, Myasthenia Gravis, Guillain-Barre syndrome, Kawasaki disease, ITP, and others) - Forecast to 2023

Market Synopsis of Global Intravenous Immunoglobulin (IVIg) Market:

Market Scenario:

Global Intravenous Immunoglobulin (IVIg) Market is growing moderately. IVIg is concerned with the treatment of patients who have weak immune system. Human body produces enough antibodies to fight infection causing germs, but if patients is suffering from immune deficiency then body can’t produce enough of them. The increasing demand for alternate immunoglobulin replacement therapies, new innovations, increasing R&D funding, developing healthcare infrastructure and increasing healthcare expenditure are major driving forces of the market. The Global Intravenous Immunoglobulin (IVIg) market is growing at the CAGR of ~5.9% during the forecast period and expected to reach US$ 8337.2 million by 2023.

Study objectives of Global Intravenous Immunoglobulin (IVIg) Market:

- To provide detailed analysis of the Global Intravenous Immunoglobulin (IVIg) market structure along with forecast for the next 7 years of the various segments and sub-segments of the IVIG Market
- To provide insights about the key drivers and restraints that affecting the growth of the IVIg market
- To provide detail analysis of global IVIg market mainly based on Value chain analysis, PROTER’s five forces, Price analysis, and Supply Chain analysis etc.
- To provide revenue of the market that includes historical as well as forecast revenue, on the basis of segments and sub segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide detail analysis of the market that segmented on the basis of type, application, and its sub-segments.
- To provide detail country level analysis of the market with respect to the current market size and future prospective
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global IVIg Market
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

FIGURE 1  Global Intravenous Immunoglobulin (IVIg) Market, By Type
Intended Audience

- Intravenous Immunoglobulin (IVlg) medicines manufacturers and suppliers
- Government and Independent Regulatory Authorities
- Medical Research laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Research Methodology:

- Interviews and cold calls with KOLs from disseminated supply side of the market
- Quantitative Primary surveys
- Demand side includes doctors, general physicians, and other medical professionals
- Supply side includes manufacturers, wholesalers, retailers

Segments:

Global Intravenous Immunoglobulin (IVlg) Market has been segmented on the basis of type which comprise IgA (sub-segments- IgA1 and IgA2), IgD, IgE, IgG. On the basis of application it segmented into CIDP (Progressive, Recurrent, Monophasic), Hypogammaglobulinemia (sub segments- AGM1, AGM2, AGM3, AGM4, AGM5, AGM6), Multifocal Motor Neuropathy, Immunodeficiency diseases (sub segments- X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), severe combined immunodeficiency), Primary Humoral Immunodeficiency (Subsegments- B cell (antibody) deficiencies, T cell deficiencies, Combination B and T cell deficiencies, Defective phagocytes, Complement deficiencies, Unknown (idiopathic)), Myasthenia Gravis (Sub segments- generalized myasthenia gravis, ocular myasthenia gravis, Congenital myasthenia gravis, Transient neonatal myasthenia gravis), Guillain-Barre syndrome (Sub segments- Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher syndrome (MFS), Acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN)), Kawasaki disease, ITP (Sub segments- acute and chronic), and others.

Regional Analysis of Global Intravenous Immunoglobulin (IVlg) Market:

Considering the global scenario of the market, North America is believed to be the largest market for Global IVlg. Moreover the European market, especially Western Europe is growing and second largest market for Global IVlg. On the other hand, Asia-Pacific is expected to grow at significant rate in the Global IVlg market during the forecasted period. Middle East and Africa is likely to have a limited but steady growth in the market, particularly market in North Africa is growing as compared to South and East region of Africa due to less awareness of these therapies and treatment.

Key Players for Global Intravenous Immunoglobulin (IVlg) Market:
Some of the key players in this market are: ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG (Germany), China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), Kedrion S.p.A (us), Octapharma (Switzerland), Shire (Republic of Ireland), AND others.

The report for Global Intravenous Immunoglobulin (IVIg) Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Contents:

1. Report Prologue
2. Introduction
   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations
   2.3 Market Structure
   2.4 Market Segmentation
3. Research Methodology
   3.1 Research Process
   3.2 Primary Research
   3.3 Secondary Research
   3.4 Market Size Estimation
   3.5 Forecast Model
4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Mega Trends
   4.5 Macroeconomic Indicators
5. Market Factor Analysis
   5.1 Value Chain Analysis
   5.2 Porters Five Forces
   5.3 Demand & Supply: Gap Analysis
   5.4 Pricing Analysis
   5.5 Investment Opportunity Analysis
   5.6 Merger and Acquisition Landscape
   5.7 Upcoming trends
   5.7.1 Market trends
   5.7.2 Technological trends
   5.7.3 Insurance & Regulations
   5.7.4 Others
6. Global Intravenous Immunoglobulin (IVIg) Market by Type
   6.1 IgA
   6.1.1 IgA1
   6.1.2 IgA2
   6.2 IgD
   6.3 IgE
6.4 IgG
6.5 IgM

7. Global Intravenous Immunoglobulin (IVIg) Market by Application

7.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.1.1 Progressive
7.1.2 Recurrent
7.1.3 Monophasic

7.2 Hypogammaglobulinemia
7.2.1 AGM1
7.2.2 AGM2
7.2.3 AGM3
7.2.4 AGM4
7.2.5 AGM5
7.2.6 AGM6

7.3 Multifocal Motor Neuropathy

7.4 Immunodeficiency diseases
7.4.1 X-linked agammaglobulinemia (XLA)
7.4.2 Common variable immunodeficiency (CVID)
7.4.3 Severe combined immunodeficiency

7.5 Primary Humoral Immunodeficiency
7.5.1 B cell (antibody) deficiency
7.5.2 T cell deficiencies
7.5.3 Combination BT cell deficiencies
7.5.4 Defective phagocytes
7.5.5 Complement deficiencies
7.5.6 Unknown (idiopathic)

7.6 Myasthenia Gravis
7.6.1 Generalized myasthenia gravis
7.6.2 Ocular myasthenia gravis
7.6.3 Congenital myasthenia gravis
7.6.4 Transient neonatal myasthenia gravis

7.7 Guillain-Barre syndrome
7.7.1 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
7.7.2 Miller Fisher syndrome (MFS)
7.7.3 Acute motor axonal neuropathy (AMAN)
7.7.4 Acute motor-sensory axonal neuropathy (AMSAN)

7.8 Kawasaki disease

7.9 ITP
7.9.1 Acute
7.9.2 Chronic

7.9 Others

8. Global Intravenous Immunoglobulin (IVIg) Market by Region

8.1 Introduction
8.2 America
8.2.1 North America
8.2.1.1 The US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
  8.3.1 Western Europe
    8.3.1.1 Germany
    8.3.1.2 France
    8.3.1.3 Italy
    8.3.1.3 Spain
    8.3.1.5 UK
    8.3.1.6 Rest of Western Europe
  8.3.2 Eastern Europe
  8.4 Asia
    8.4.1 China
    8.4.2 India
    8.4.3 Japan
    8.4.4 South Korea
    8.4.5 Rest of Asia
  8.5 Pacific
  8.6 Middle East and Africa
    8.6.1 UAE
    8.6.2 Saudi Arabia
    8.6.3 Egypt
    8.6.4 Rest of Middle East and Africa

9 Conclusion
  9.1 Key findings
    9.1.1 From CEO's viewpoint
    9.1.2 Unmet needs of the market
  9.2 Key companies to watch
  9.3 Prediction of medical robots industry

10 Appendix